2020 Hilton Head Annual Conference – Online Track

Registration Now Open!

Sign Up


University Track Online: August 24-28, 2020, 7:00 - 9:00 pm

Post-Conference Accredited Courses: Focus on Cardiology, Oncology, Multiple Sclerosis and Thyroid.

Free with the 2020 Annual International Restorative Medicine Conference registration, this package of recorded webinars is valued at $450. CMEs have been applied for and are pending. Participants must view webinars live to earn credits. Conference attendees will receive a link to access the online webinars after the live conference concludes.

Five CME credits will be made available by reading Journal of Restorative Medicine articles and passing related quizzes.

Faculty members and topics for the Post-Conference webinars are:

Mark Houston, M.D., M.S., MSc, ABAARM, FAARM, FACP, FAHA, FASH, FACN, FAARM, DABC

Dr. Houston is tripled boarded in hypertension as an American Society of Hypertension (ASH) specialist and Fellow of the American Society of Hypertension (FASH), Internal Medicine (ABIM) and Anti-aging medicine (ABAARM). He also has a Masters degree in Human Nutrition from the University of Bridgeport, Connecticut and a Masters of Science degree in Functional and Metabolic Medicine from the University of South Florida in Tampa. The Hypertension Institute was founded in 1995 by Dr. Mark Houston, internist and hypertension and cardiovascular specialist, and Dr. Allen Naftilin, cardiologist and hypertension specialist, at St. Thomas West Hospital and St. Thomas West Hospital in Nashville, TN. The Hypertension Institute immediately received national acclaim as one of the leading Institutes in the US for the treatment of hypertension and related cardiovascular disorders. In 2000, the Hypertension Institute was recognized as one of the top Cardiovascular Centers in the Southeast by the Consortium of Southeastern Hypertension Centers (COSEHC).

The Role of Vascular Biology, Nutrition and Nutraceuticals in the Prevention and Treatment of Hypertension and Cardiovascular Disease (August 24 2020 7pm – 9pm)

Course Objectives

-           Review the literature for the underlying mechanisms of hypertension, vascular biology.
-           Evidence-based review of the efficacy of nutrition, lifestyle factors and nutraceuticals in the prevention and treatment of cardiovascular disease.

-           Evidence based review of anti-hypertensive drug – nutrient interactions.

Dawn Lemanne, MD, MPH

Dr. Lemanne is a board certified medical oncologist and a leading integrative oncologist. She holds a faculty appointment at the University of Arizona’s Center for Integrative Medicine, is the author of peer-reviewed articles, textbook chapters, and speaks internationally by invitation. Her medical degree was completed at UCSF and she did her clinical oncology fellowship at Stanford University Hospitals. She is the winner of the 2017 American College of Nutrition, Stanley Wallach Award for Advancement of Human Understanding of Nutrition in Cancer. Her private clinic in Oregon attracts patients from around the globe.

 

Keto Anyone? Timing for Carbohydrate Restriction, Fat Restriction, or Fasting in the Cancer Clinic (August 25, 2020 7:00 pm – 9:00pm)

Patients diagnosed with cancer are searching for the “right” diet. Dietary patterns popular among cancer patients at present include the extremely low-carbohydrate ketogenic diet, moderate carbohydrate restriction, “paleo,” low fat, alkaline, and plant-based diets including vegan or raw vegan, and intermittent fasting. Peer-reviewed evidence exists for the efficacy of all of these options, but only under certain circumstances. For example, some animal research on invasive prostate cancer demonstrates that alkalization of drinking water starting in the first few weeks of life prevents development of invasive prostate cancer, whereas this maneuver is less effective if started later in life.

The ketogenic diet, defined as severe carbohydrate restriction leading to measurable blood levels of beta hydroxybutyrate, and fasting may be useful in decreasing the side effects of cancer treatment. Animal studies demonstrate an overall survival benefit in certain cancers, but only when these dietary maneuvers are timed precisely to coincide with treatment. Dr. Lemanne will review the best approaches for dietary interventions, and will clarify the conditions when keto diet or fasting is appropriate, and when it is not.

Goals and Objectives:

  • Understand how timing in the course of a cancer’s evolution determines whether a dietary intervention is effective or harmful.
  • Gain familiarity with the evidence for using moderate carbohydrate restriction in patients with breast and colon cancer.
  • Review the growing body of peer-reviewed literature on the safety and efficacy of the ketogenic diet and fasting in patients with cancer.
  • Demonstrate how the metabolic effects of fasting differ from the metabolic effects of caloric restriction, and how to exploit these differences
  • Review the evidence-based advantages and limitations of the ketogenic diet in cancer therapy

Harnessing Evolution During Cancer Therapy

(August 26, 2020, 1 hour, 7:00 - 8:00pm)

 

The conventional treatment paradigm oncologists work under advises using the “maximum tolerated dose,” MTD, applied at specific, non-varying frequencies. This is an attempt to kill as many tumor cells as possible while avoiding (sometimes just barely) killing the patient. However, the drawback is competitive release of treatment resistant cells in virtually every case. MTD predictably engenders emergence of treatment-resistance in tumors, and such treatment has now been shown not to prolong survival, but to accelerate death in patients with “incurable” cancers. This lecture will explore recent mathematical modeling and early clinical research that has successfully challenged that approach. This work has resulted in a new treatment paradigm called “adaptive therapy,” under study at Moffitt Cancer Center at the University of South Florida, Arizona State University, and Cleveland Clinic. In cancer treatment, the adaptive therapy approach uses small doses of several antineoplastic pharmaceuticals with varying mechanisms, applied singly or in combination, and at intervals varying based on tumor burden. Integrated into this approach are evidence-based dietary maneuvers, such as carbohydrate restriction, exercise, hyperbaric oxygen therapy, etc. These may require specific timing in tumor evolution and treatment for optimal benefit. The success of the “adaptive therapy” approach is predicted by mathematical models of cancer treatment employing “game theory.” The success of adaptive therapy over MTD has been corroborated in early clinical trials in patients with advanced metastatic prostate cancer and small cell lung cancer.

Goals and Objectives:

  • Discuss the evolutionary reasons behind Peto’s paradox: why some multicellular organisms rarely develop cancer, and why humans are prone to cancer.
  • Discuss the limitations of the “maximum tolerated dose” paradigm when used in treatment of most advanced, incurable metastatic cancers of adults, and contrast it with the “adaptive therapy” model based on a review of research.
  • Review evidence-based support on why adaptive therapy for advanced, metastatic, incurable cancers of adults may be preferred to the older paradigm of “maximum tolerated dose.”
  • Review research on why dietary maneuvers such as carbohydrate restriction (such as the ketogenic diet) or dietary alkalization may be particularly powerful when timed to specific moments in tumor evolution.
  • Understand the limits of “adaptive therapy,” and list the oncologic conditions wherein adaptive therapy should be avoided

 

 

Reinhold Vieth, Ph.D, F.C.A.C.B.

Dr Reinhold Vieth is a Professor in the Department of Nutritional Sciences, and the Department of Laboratory Medicine and Pathobiology, University of Toronto.  He is an internationally recognized expert on the clinical nutrition of vitamin D as well as its pharmacology and safety.  His research has followed the path of vitamin D from the basic science lab, to bone health and osteoporosis, to breast and prostate cancers.  His current focus includes the role of vitamin D deficiency in gestational diabetes, and multiple sclerosis, including clinical trials of vitamin D treatment.  The American Journal of Clinical Nutrition, lists four of Dr Vieth’s publications among its list of top-25 most read articles.  He is professionally certified as a Clinical Chemist, and at Mount Sinai Hospital in Toronto, is Director of the Bone and Mineral Laboratory, as well as Director of Point of Care Testing.

 

Vitamin D beyond bone health: Primary prevention and therapeutic potentials in the contexts of Multiple Sclerosis and Prostate Cancer.

(August 26 8:00-9:00pm)

Course Objectives:

  1. Summarize Evidence Based Research about vitamin D in the context of prevention and treatments for bone health, prostate cancer and multiple sclerosis
  2. Differentiate unresolved issues pertinent to prevention and treatment of these diseases
  3. Address the risk and benefits profiles about the use of vitamin D supplementation/treatment
  4. Explain why it is unrealistic to expect that double blind randomized trials will ever provide evidence that vitamin D can prevent prostate cancer or multiple sclerosis.

 

Mimi Guarneri, MD, FACC

Dr. Mimi Guarneri is Board-certified in Cardiovascular Disease, Internal Medicine, Nuclear Cardiology, and Integrative Holistic Medicine. Dr. Guarneri is a Founder and President of The Academy of Integrative Health and Medicine. She serves on the Founding Board of the American Board Physician Specialties in Integrative Medicine, and is a Clinical Associate Professor at University of California, San Diego. An award-winning physician and researcher, she has been recognized for her national leadership in Integrative Medicine by the Bravewell Collaborative, and she served as chair of the Bravewell Clinical Network for Integrative Medicine.  After graduating number one in her class at SUNY Medical Center in New York, Dr. Guarneri began her career at Scripps Clinic as an attending in interventional cardiology, where she placed thousands of coronary stents.  Recognizing the need for a more comprehensive and holistic approach to cardiovascular disease, she founded the Scripps Center for Integrative Medicine and served as Medical Director for 15 years, where state-of-the-art cardiac imaging technology and lifestyle change programs could be used to aggressively diagnose, prevent and treat cardiovascular disease. She has served as a senior advisor for large healthcare systems to develop integrative medicine and wellness centers.

Beyond Cholesterol: Predictive, Pro-Active Health

(August 27, 2020 7:00pm – 9:00pm)
-           Evidence-based review of the efficacy of nutrition, lifestyle factors and nutraceuticals in the prevention and treatment of chronic diseases including diabetes, hypercholesterolemia, and atherosclerosis.

-           Evidence based review of stress, cortisol, DHEA and the microbiome.

-           Evidence based review of meditation and its effect on cardiovascular disease.

 

Antonio C. Bianco, MD, PhD

Antonio Bianco is a physician-scientist working in the thyroid field. His studies have focused on how the systemic hormone T3 initiates or terminates critical biological steps while maintaining relatively stable levels in the circulation. As a graduate student, he discovered the molecular link between deiodination and thermogenesis, specifically that the UCP-1 gene, key for brown adipose tissue thermogenesis, is transcriptionally stimulated by T3. This finding inspired further research on how deiodinases can modify intracellular T3 levels and signaling without antecedent changes in plasma TH levels. Over the years, the work in his lab has established the importance of “local” control of TH metabolism provided by deiodinases. From a broad perspective, this work has inspired the modern paradigm that deiodinases regulate thyroid hormone signaling on a tissue-specific basis, playing critical roles in human health and disease. He also served in different administrative capacities and as President of the American Thyroid Association (2015-16).

Thyroid Hormone Deiodination and Its Clinical Implications

August 28 7:00 – 8:00pm

 

Course Objectives:

-           Review of Hypothalamus, pituitary, thyroid axis.

-           Evidence based review Dio2 gene polymorphism Thr92Ala

-           Evidence based review of treatments for hypothyroidism.

 

Using Serum TSH as Biological Index of Thyroid Function

August 28 8:00 – 9:00pm

Course Objectives:

-           Review of Hypothalamus, pituitary, thyroid axis.

-           Evidence based review of treatments for hypothyroidism.


Register Now

Expand Your Practice With New Clinical Skills

What the Attendees Say


See All Testimonials

Questions?

If you have a question or problem registering, please email conferences@restorativemedicine.com or call toll-free 866-962-2276